Back to top
more

Pacific Biosciences of California (PACB)

(Real Time Quote from BATS)

$1.32 USD

1.32
4,116,837

-0.01 (-0.75%)

Updated Aug 4, 2025 02:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.

Zacks Equity Research

PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.

Zacks Equity Research

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings gain from strong performance at MedSurg and Neurotechnology and Spine units.

Zacks Equity Research

Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.

Zacks Equity Research

ABIOMED (ABMD) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.

Zacks Equity Research

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter earnings benefit from solid segmental performance and growth across all geographies.

Zacks Equity Research

Will Pacific Biosciences of California (PACB) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.

Zacks Equity Research

Masimo (MASI) Q1 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Masimo (MASI) sees solid growth in key Product segment in Q1.

Zacks Equity Research

Here's Why You Should Retain Inogen (INGN) Stock for Now

by Zacks Equity Research

Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.

Zacks Equity Research

Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec

by Zacks Equity Research

Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.

Zacks Equity Research

Why Is Pacific Biosciences (PACB) Down 18.1% Since Last Earnings Report?

by Zacks Equity Research

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Can PennyMac (PFSI) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

PennyMac (PFSI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Ensign Group (ENSG) Stock

by Zacks Equity Research

Ensign Group (ENSG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4

by Zacks Equity Research

Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 100.00% and 9.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Pacific Biosciences Stock Now

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Zacks Equity Research

Pacific Biosciences (PACB) Up 2.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Hold on to Pacific Biosciences Stock

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Zacks Equity Research

Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock

by Zacks Equity Research

Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.

Zacks Equity Research

Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -26.67% and -21.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Pacific Biosciences of California (PACB) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.